Cardiovascular Drugs Market Size & Share

1. Global Cardiovascular Drugs Market Analysis The global cardiovascular drugs market reached USD 59.29 billion in 2024 and is projected to grow to USD 80.44 billion by 2032, with a compound annual growth rate (CAGR) of 3.9%. Market Leadership North America dominates the market with a 45.31% share in 2024, driven by:  High prevalence of cardiovascular diseases  New product launches  Increased R&D initiatives  Greater awareness of risk factors like diabetes Key Market Segments By Drug Type  Anticoagulants hold the largest market share and highest CAGR  Antihypertensive drugs represent the second-largest segment  Other segments include antihyperlipidemic and antiplatelet drugs By Distribution Channel 1.Hospital pharmacies (dominant share) 2.Retail pharmacies (second largest) 3.Online pharmacies (highest projected CAGR) Major Industry Players Leading companies include:  Bristol-Myers Squibb Company  Pfizer Inc.  Bayer AG  Janssen Pharmaceuticals  AstraZeneca  Sanofi  Novartis AG Market Drivers The market growth is propelled by:  Increased awareness of cardiovascular health  Rising demand for effective therapeutics

2.  Introduction of advanced drugs like Eliquis  Growing prevalence of cardiovascular diseases globally Clinical Development Insights Phase distribution of discontinued cardiovascular drugs (2011-2022):  Phase 2: 45.2%  Phase 1: 36.7%  Phase 3 and Preclinical: <25% combined Recent Industry Developments Key developments in 2025:  FDA approval of additional indication for Janssen's Xarelto  Launch of Anthos Therapeutics by Novartis and Blackstone  Introduction of valsartan-sacubitril by Natco Pharma Report- Fortune Business Insights - Cardiovascular Drugs Market Size, Share & Growth Report, 2032 https://www.fortunebusinessinsights.com/industry-reports/cardiovascular-therapeutics-market- 100379